. In the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor suppressors: PTEN, which antagonizes PI3K and therefore inhibits Akt, and TSC1/TSC2 heterodimer, which inhibits mTOR by inhibiting the activity of Rheb Akt activates mTOR via direct phosphorylation of TSC2 and by the inhibition of AMPK, thereby activating Rheb and mTOR-Raptor activity. Upon activation, mTOR-Raptor activates S6K and inhibits 4E-BP to accelerate mRNA translation, and also initiates feedback inhibition of Akt, which is at least in part mediated by S6K (for details see text).
mammalian cells (Lawlor and Alessi, 2001 ). However, it remains to be determined which downstream effectors of Akt are most critical for the genesis of cancer. Several lines of evidence point to the two most evolutionarily conserved downstream effectors, the forkhead family of transcription factors, FOXO, and the mammalian target of rapamycin, mTOR (Figure 1 ). FOXO transcription factors, which inhibit mammalian cell proliferation, are directly phosphorylated and inactivated by Akt (Tran et al., 2003) , whereas mTOR, which is associated with increased cell proliferation, is indirectly activated by Akt.
The interplay between Akt and mTOR
One mechanism whereby Akt can activate mTOR is through direct phosphorylation of tuberous sclerosis complex 2 (TSC2), which otherwise inhibits mTOR activity (Figure 1 ; Hay and Sonenberg, 2004) . Tuberous sclerosis complex 1 (TSC1) and TSC2 form a heterodimer with GTPase activity that inhibits the activity of Rheb, a small GTPase required for mTOR activation ( Figure 1 ; Hay and Sonenberg, 2004) . This mechanism of mTOR activation by Akt is conserved in Drosophila. In addition, TSC2 is directly phosphorylated and activated by AMPK (Inoki et al., 2003) , and Akt inhibits AMPK activity, via its role in energy metabolism, to fully inhibit TSC2 and activate mTOR (HahnWindgassen et al., 2005) . Thus, activation of Akt could also inhibit the tumor suppressor activity of AMPK kinase, LKB1 (Figure 1 ). Germline mutations in the genes encoding TSC1 and TSC2 are associated with the dominant genetic disorder, tuberous sclerosis (TSC), which is characterized by the development of benign tumors (hamartomas), and thus, TSC1 and TSC2 are considered tumor suppressors (Kwiatkowski, 2003) . Therefore, in the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor suppressors, which attenuate the pathway: PTEN, which acts upstream of Akt, and TSC1/TSC2 heterodimer, which acts downstream of Akt and upstream of mTOR.
Upon activation, mTOR, which forms a rapamycin-sensitive complex with Raptor (regulatory-associated protein of mTOR), increases mRNA translation via activation of S6-kinase and inhibition of eIF4E binding protein (4E-BP) (Figure 1 ; Hay and Sonenberg, 2004) . TSC1 or TSC2 deletion constitutively activates rapamycin-sensitive functions of mTOR independently of Akt. In contrast, Akt activity is inhibited when mTOR is activated in TSC1 or TSC2 deficient cells via a negative feedback regulatory loop (Figure 1 ). This feedback inhibitory loop appears to be conserved in Drosophila (Radimerski et al., 2002) and has been attributed to the inhibitory effect of S6 Kinase (a downstream effector of mTOR) on insulin receptor substrate-1 (IRS-1), which mediates PI3K activation by insulin and IGF-1 (Harrington et al., 2005) . However, this is unlikely to be the only mechanism that accounts for the negative feedback. A more general mechanism must exist, because Akt activity is not significantly elevated in TSC null cells, even when stimulated with serum or PDGF (platelet-derived growth factor) (Zhang et al., 2003) . The relationship between Akt and mTOR is further complicated by the existence of mTOR-Rictor (rapamycin-insensitive companion of mTOR) complex, which possesses the rapamycin-insensitive mTOR activity. The mTOR-Rictor complex has a conserved activity that regulates the actin cytoskeleton (Jacinto et al., 2004; Sarbassov et al., 2004) . Recent reports provide evidence that mTOR-Rictor possesses PDK2 activity, phosphorylating the serine residue in the C-terminal hydrophobic motif of Akt, and therefore essential for Akt activity (Sarbassov et al., 2005) .
Despite the inhibition of Akt and the activation of FOXO (Manning et al., 2005) , immortalized Tsc2 null cells proliferate at the same rate or faster than wild-type cells and remain susceptible to oncogenic transformation to a comparable or greater extent relative to wild-type cells (Zhang et al., 2003; Ma et al., 2005a; C.C. Chen, J. Skeen, and N. Hay, unpublished data) . This raises the possibility that mTOR may constitute the most critical downstream effector of Akt with respect to cell proliferation, tumorigenesis, and possibly cell survival. In cultured cells, mTOR inhibition by rapamycin attenuates cell cycle progression and, in some cases, elicits apoptosis (Hay and Sonenberg, 2004) . The rapamycin analog CCI-779 attenuates tumor growth in Pten +/− mice predisposed to developing a diverse array of neoplasia (Podsypanina et al., 2001) , as well as in cancer cells lacking functional PTEN . Furthermore, transgenic mice expressing activated Akt in the prostate develop prostate intraepithelial neoplasia (PIN), which is antagonized by the rapamycin analog RAD001 (Majumder et al., 2004) . Also, overexpression of eIF4E, a downstream effector of mTOR, in mouse B cell lymphoma accelerates tumorigenesis and mimics the neoplastic effect of activated Akt in these cells (Wendel et al., 2004) . The critical role that mTOR and mRNA translation play in tumorigenesis is reinforced by the observation that the primary effects of oncogenic Ras or Akt on gene expression are via induction of mRNA translation (Rajasekhar et al., 2003) . The contention that mTOR executes the most critical functions of Akt with regards to cell growth and proliferation is supported by genetic studies in Drosophila. In Drosophila, both pten deletion and the loss of either tsc1 or tsc2 result in similar phenotypes characterized by increased cell size and cell proliferation. Genetic epistasis analyses in Drosophila have shown that cells doubly deficient for akt (or overexpressing PTEN) and either tsc1 or tsc2 mimic the phenotype induced by tsc1 or tsc2 inactivation (Potter et al., 2001) . Similarly, cells doubly deficient for pten and tor are indistinguishable from cells lacking tor alone, which are characterized by reduced cell size and impaired proliferation (Zhang et al., 2000) . Thus, in Drosophila, TSC1/TSC2 and TOR are epistatic to PTEN and Akt. Based on these observations, one might expect that mutations in the genes encoding the tumor suppressors TSC1 and TSC2 should be frequently observed in a wide spectrum of human cancers, as is observed for PTEN. However, unlike mutations in the pten gene, mutations in either tsc1 or tsc2 gene have not yet been identified in sporadic human cancers (Kwiatkowski, 2003) . Moreover, tuberous sclerosis patients with inherited mutations in either Tsc1 or Tsc2 develop hamartomas in multiple organs, but rarely develop malignant cancers (Kwiatkowski, 2003) . In contrast, patients with Cowden disease that harbor Pten gene mutations develop similar lesions but are predisposed to malignant cancer development (Eng, 2003) . Also, when tuberous sclerosis patients do develop malignant cancer, it is generally restricted to certain types of tumors such as renal cell carcinoma or angiomyolipomas (Kwiatkowski, 2003) . Finally, unlike Pten +/− mice that are predisposed to multiple neoplasia, Tsc2 +/− mice develop mainly kidney tumors and hepatic hemangioma and, depending on the genetic background, also lung adenoma and angiosarcoma (Kobayashi et al., 1999; Onda et al., 1999) . Taken together, these observations raise the question of why TSC1/TSC2 deficiency does not recapitulate the PTEN deficiency in respect to cancer. One possibility is that in vivo, the Akt inhibition mediated by mTOR activation impedes the tumor progression promoted by TSC1/TSC2 deficiency. Independent studies by two different groups have attempted to address this M I N I R E V I E W issue in vivo in the mouse. Since complete loss of either PTEN or TSC2 leads to embryonic lethality, both groups employed Pten +/− , Tsc2 +/− , and Pten +/− Tsc2 +/− mice to address this question (Ma et al., 2005b; Manning et al., 2005) . Although the source of Pten +/− mice utilized in both studies was the same, the source of Tsc2 +/− mice was different. The Tsc2 +/− mice used by Ma et al. predominantly develop renal carcinoma and, after a long latent period, hepatic hemangiomas (Kobayashi et al., 1999) , whereas the Tsc2 +/− mice used by Manning et al. develop hepatic hemangiomas and angiosarcomas in addition to kidney tumors (Onda et al., 1999) .
Based on the epistasis analyses in Drosophila, the deficiency in TSC2 is expected to increase the phenotype of PTEN deficiency, whereas the deficiency in PTEN is not expected to enhance the phenotype of TSC2 deficiency. Indeed, both groups found that Pten +/− Tsc2 +/− mice display enhanced lymph node hyperplasia, which is observed in Pten +/− mice and is the main cause of death of these mice, and therefore there is a significant decrease in the life span of Pten +/− Tcs2 +/− mice in comparison with Pten +/− mice. However, Manning et al. did not find that TSC2 haplodeficiency enhances the endometrium and prostate neoplasia, gastrointestinal polyps, or thyroid and adrenal medulla tumors, which are typically found in Pten +/− mice. In contrast, Ma et al. found that haplodeficiency of TSC2 accelerates the development of prostatic neoplasia in Pten +/− mice, since PIN rarely progresses to carcinoma in Pten +/− mice, whereas progression to carcinoma is frequently observed in Pten +/− Tsc2 +/− mice. In addition, they found that a small percentage of the doubly heterozygous mice developed skin cancer, which was not observed in either of the singly heterozygous mice. Consistent with what could be extrapolated from the epistasis analyses in Drosophila, Ma et al. found that PTEN haplodeficiency did not enhance renal carcinoma development in their Tsc2 +/− mice. Manning et al., however, found that haplodeficiency of PTEN, which only modestly accelerated kidney adenomas, dramatically decreased the latency and increased the penentrance of liver hemangiomas and angiosarcomas in Tsc2 +/− mice. Both groups attributed the differences in their results to the different genetic background of the mice used in these studies. Interestingly, both groups found that the feedback inhibition of Akt induced by TSC2 deficiency is alleviated by PTEN haplodeficiency.
Collectively, the results of these studies do not provide a conclusive explanation for the lack of mutations in Tsc genes in sporadic cancers, or for the limited spectrum of tumors induced by TSC2 deficiency. Nevertheless, based on their results, Manning et al. suggested that the feedback inhibition of Akt induced by the deletion of TSC2 impedes the progression of cancer, and that when PTEN level is also reduced, the restored Akt activity enables faster tumor progression. How does restoration of Akt activity in Tsc2 +/− mice contribute to tumorigenesis? As tumorigenesis is a multistep process, which requires multiple genetic lesions, it is conceivable that Akt activation accelerates the mutation rate, including the loss of heterozygosity (LOH) of Tsc2 observed in tumors of Tsc2 +/− mice. Notably, activation of Akt or deletion of PTEN could overcome a G2 cell cycle checkpoint and accelerate mutagenesis (Kandel et al., 2002; King et al., 2004; Puc et al., 2005) . In addition, accelerated mRNA translation and ribosomal biogenesis induced by the deficiency of TSC2 consume high levels of cellular energy. Since Akt is required to maintain cellular energy metabolism (Hahn-Windgassen et al., 2005) , the limited intracellular ATP in Tsc2 null cells could inhibit their survival and proliferation, in particular within a neoplastic lesion, an environment where nutrients and oxygen have more restricted availability, unless Akt activity is restored. Other prooncogenic activities of Akt, particularly its antiapoptotic activities, are also likely to contribute.
Based upon their results, Ma et al. have provided an alternate explanation for the discrepancy between Pten and Tsc2 mutational frequencies in cancer. These authors found that while tumors initiated by Tsc2 heterozygosity develop only after LOH, tumors initiated by Pten heterozygosity can develop in the absence of LOH. This raised the possibility that PTEN is a haploinsufficient tumor suppressor. Because they also found that tumors initiated by Pten heterozygosity are accelerated by Tsc2 heterozygosity but do not exhibit LOH at either of the two genes, they concluded that TSC2 also constitutes a haploinsufficient tumor suppressor for certain types of cancer.
Are PTEN and TSC2 haploinsufficient tumor suppressors?
According to the classic tumor suppressor two-hit paradigm defined by Knudson, a germline mutation in a tumor suppressor gene is followed by the loss of function of the other allele during tumor development via genetic or epigenetic mechanisms. However, whether PTEN follows that rule is controversial. Although biallelic PTEN inactivation is frequently observed in several types of cancer, the loss of a single allele, with the preservation of the other allele, is also common. For instance, LOH at 10q23, the chromosomal localization of PTEN, was reported to occur in over half of human metastatic prostate cancers, but only a third of these cases display biallelic PTEN intragenic mutations (Suzuki et al., 1998b) . This, however, does not completely rule out the possibility that the expression of or the activity of PTEN is either reduced or lost by other documented epigenetic mechanisms (Kurose et al., 2001) . Likewise, despite the absence of Pten LOH in neoplastic lesions described by Ma et al., reduced PTEN function by inactivating mutations in the preserved allele cannot be fully excluded, as this was not exhaustively examined. Furthermore, these results seemingly contradict those reported by others demonstrating Pten LOH in lymphoma, endometrial carcinoma, adrenal tumors, and prostatic neoplasia in Pten +/− mice (Podsypanina et al., 1999; Podsypanina et al., 2001; Suzuki et al., 1998b) . Clearly, the long latency period required for neoplasia development in Pten +/− mice, which is markedly shortened in the complete absence of PTEN (Trotman et al., 2003; Wang et al., 2003) , suggests that the expression and/or activity of the remaining wild-type Pten allele is somehow affected in this process in Pten +/− mice. Nevertheless, the absence of LOH at the Pten locus in the lymph node hyperplasia of Pten +/− mice suggests that haplodeficiency of PTEN is sufficient to confer some cell survival and possibly proliferative advantage to cause preneoplastic lesions. The transition to high-grade neoplasia requires additional modifying mutations, including those affecting the wild-type Pten allele. The list of candidate modifier genes would ostensibly include regulators of mTOR activity, given the fact that tumorigenesis is enhanced in Pten +/− Tsc2 +/− mice.
Unlike PTEN, both TSC1 and TSC2 follow the classical tumor suppressor two-hit paradigm in human tumors (Kwiatkowski, 2003) , and LOH is usually observed in tumors developed in Tsc2 +/− mice (Kobayashi et al., 1999; Onda et al., 1999) . However, Ma et al. found that in the prostate neoplasia of Pten +/− Tsc2 +/− mice, there is no Tsc2 LOH, suggesting that when PTEN levels are reduced, TSC2 is haploinsufficient to suppress tumorigenesis. Indeed, they found that, at least ex vivo, mouse embryonic fibroblasts doubly heterozygous for Pten and Tsc2 exhibit elevated mTOR activity when compared with their singly heterozygous counterparts. This is consistent with the results of Manning et al. showing that Pten +/− Tsc2 +/− hyperplastic lymph nodes display elevated mTOR activity in the absence of LOH. Thus, it is not immediately clear why there is a loss of TSC2 in kidney tumors and hepatic hemangiomas derived from Pten +/− Tsc2 +/− mice (Kwiatkowski, 2003) . Also, if indeed TSC2 is haploinsufficient to suppress tumor development on the background of other mutations, which enhance PI3K activity, it is not clear why TSC patients rarely develop malignant cancer, which is restricted only to certain cell types. Obviously, more studies are required to resolve this issue.
The implication of Akt-mTOR interactions for cancer therapy
The studies by Ma et al. and Manning et al. underscore the importance of Akt-mTOR interrelationships for the progression and therapy of cancer. Akt and mTOR are linked to each other via positive and negative regulatory circuits, which restrain their simultaneous hyperactivation (Figure 2 ). This might have been evolved as a protection mechanism to inhibit uncontrolled cell survival and proliferation. As indicated above, the feedback inhibition of Akt induced by hyperactivation of mTOR rapamycinsensitive activity was attributed to the inhibitory effect of S6 kinase on IRS-1 downstream of IGF-1 and insulin receptors. However, the inability of serum or PDGF to overcome this inhibition, together with the finding by Ma et al. and Manning et al. that the feedback inhibition also occurs in vivo in mouse tissues that are exposed to a variety of growth factors, which activate their cognate receptors and PI3K, points to a more general mechanism. Since haplodeficiency of PTEN is sufficient to alleviate the feedback inhibition, one possibility is that hyperactivation of the rapamycin-sensitive activity mTOR could elevate PTEN activity. Alternatively, the existence of two mTOR complexes may explain the inhibitory feedback. As indicated above, mTOR exists in two separate complexes, the mTOR-Raptor, a rapamycin-sensitive complex, which is activated by Akt, and the mTOR-Rictor, a rapamycin-insensitive complex, which is activated by growth factors and possesses PDK2 activity (Sarbassov et al., 2005) . If mTOR-Rictor is indeed the principal PDK2, following growth factor stimulation, the mTOR-Rictor complex activates Akt. When activated, AKT inhibits the activity of TSC1/TSC2 heterodimer to activate Rheb, which in turn promotes the formation of mTOR-Raptor complex to activate the rapamycin-sensitive activity of mTOR. Assuming that an equilibrium exists between these two complexes within the cell, when the mTOR-Raptor complex is formed, it could antagonize the formation of mTOR-Rictor complex and therefore reduce Akt activity (Figure 2 ). Although speculative, this could provide, in addition to the documented specific mechanisms (Harrington et al., 2005; Zhang et al., 2003) , a simple general mechanism for the feedback inhibitory loop. Thus, when mTOR-Raptor is activated independently of Akt, via the deletion of TSC1/TSC2, it may inhibit the formation of mTOR-Rictor complex and therefore also Akt activation (Figure 2 ). This is also compatible with the observation that knockdown of Raptor increases Akt activity (Sarbassov et al., 2005) . Because PDK2 activity is dependent on PI3K, it is conceivable that reduced activity of PTEN would enhance mTOR-Rictor activity and therefore alleviate the inhibition of Akt by the hyperactive mTOR-Raptor complex in TSCdeficient cells.
The rapamycin derivatives CCI-779, RAD001, and AP23573
M I N I R E V I E W Figure 2.
An equilibrium between mTOR-Raptor and mTOR-Rictor complexes could provide an alternative mechanism for the feedback inhibition of Akt by mTOR
A:
In wild-type cells, the activation of receptor tyrosine kinase (RTK) leads the activation of PI3K. PI3K then leads to the activation of Akt by inducing its translocation to the plasma membrane and its phosphorylation by PDK1 and by mTOR-Rictor (PDK2). Upon activation, Akt induces the assembly of the active mTOR-Raptor complex. The assembly of mTOR-Raptor active complex inhibits the assembly of the mTOR-Rictor active complex, and thereby inhibits Akt. However, in wild-type cells, this inhibition is transient, because the inhibition of Akt would eventually inhibit mTOR-Raptor. B: In TSC-deficient cells, mTOR-Raptor active complex is constitutively active, thereby reducing mTOR-Rictor activity and therefore also Akt activity. C: In cells doubly deficient for PTEN and TSC, PI3K is hyperactivated, leading to the hyperactivation of mTOR-Rictor and thereby restoring Akt activity.
are currently being investigated in clinical trials for cancer therapy (Vignot et al., 2005) . However, because the primary activity of rapamycin is to attenuate cell cycle progression and cell growth, it is not presently clear whether these agents are simply cytostatic or can also eliminate tumor cells by inducing cell death. Moreover, because of the negative regulatory loop, rapamycin can elevate Akt activity (Harrington et al., 2005) , this could pose a significant strategic dilemma when designing cancer therapies using these compounds, unless prolonged rapamycin treatment also impairs mTOR-Rictor complex activity and consequently Akt activity. In principle, therefore, therapeutic approaches that simultaneously target both Akt and mTORRaptor may ultimately prove more efficacious.
